Does a Spate of Manager Departures at T. Rowe Price Signal Trouble?
Three key stock fund managers have left or are leaving soon. If you invest in Price funds, here’s what to do now.

Corporate culture is, in my view, a key determinant of a fund company's success. This is just common sense. When people hate to come to work every morning, they don't usually do their best work. When they work together and share ideas, they tend to succeed more often than they fail.
I mention this because I was shocked to hear of the recent departures of three key U.S. stock fund managers, along with a couple of top analysts, from T. Rowe Price. I've always considered Baltimore-based T. Rowe one of the nation's best-run fund outfits. One manifestation of that is the company's low manager turnover — three managers typically leave about every five years, not in a few months. Many managers spend their entire careers at Price. So I can't help but worry whether the spate of departures signals a fundamental change at the company.
Take a look at the damage. Kris Jenner, manager of top-performing T. Rowe Price Health Sciences (symbol PRHSX), along with two health analysts, left to start a hedge fund. Under Jenner, who had run the fund since 2000, it returned an annualized 11.0% until his February 14 departure. That compares with an annualized 2.2%% over the same period for Standard & Poor's 500-stock index. Health Sciences' new manager is Taymour Tamaddon, previously an analyst at the fund.
From just $107.88 $24.99 for Kiplinger Personal Finance
Be a smarter, better informed investor.

Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
An equally big blow was the departure on May 10 of Joseph Milano, who had managed T. Rowe Price New America Growth (PRWAX) superbly since 2002. Under his stewardship, the fund returned an annualized 10.2% — an average of 1.5 percentage points per year better than the S&P 500. Milano may start a hedge fund, too.
Daniel Martino has taken over from Milano. Martino put up good numbers in 3½ years managing T. Rowe Price Media and Telecommunications Fund (PRMTX). But he lacks experience running a diversified fund or a fund as large as New America Growth, which contains $4 billion in assets.
Meanwhile, Tim Parker has announced his resignation as manager of T. Rowe Price New Era (PRNEX), a natural resources fund, after less than three years on the job. That's perplexing because Parker has worked at T. Rowe since 2001 and was groomed for years to take over New Era. Returns were mediocre under his leadership, however. Parker will leave by September 30 and be replaced by Shawn Driscoll, who has been a natural resources analyst at Price for the past seven years.
John Linehan, head of U.S. stock funds at Price, is unhappy about the cluster of resignations. But, he says, "we've seen this play before." In 2001 and 2002, four T. Rowe managers left in a short period. "Obviously, the recent turnover has been disappointing," Linehan says. "It's never any fun to go through. But it emphasizes the importance of having a deep bench. Which is why we go out and hire the best people we can find and then work hard to develop their talents so that they can be ready to take over a fund."
The company's culture hasn't changed at all, Linehan says: "Collegiality and collaboration are crucial to us. We reward people who work well with each other, trading insights and expanding on one another's investment ideas."
The manager is, of course, the most important person at any fund. Anytime a manager leaves, you need to take careful notice. At the same time, manager losses at big fund shops such as Price historically haven't been as devastating as manager departures from small firms, where the manager is pretty much synonymous with the fund.
The bottom line: I'm willing to give Linehan and T. Rowe the benefit of the doubt. But I see no reason to commit new money to any of the three affected funds. If you own them, you have a tough choice. It's hard to find a good health-sector fund as broad as T. Rowe's, which holds a healthy dose of biotech stocks as well as drug and health insurance companies. I'd probably give the new manager a year to prove himself. But I'd probably sell New America Growth — there are plenty of good growth funds. And I'd sell New Era — the natural resources sector doesn't appeal to me, anyway.
My favorite Price funds include Capital Appreciation (PRWCX), Mid-Cap Growth (RPMGX) and all of the firm's retirement funds. The retirement funds hold other Price funds, with their division between stock and bond funds becoming increasingly conservative as shareholders approach retirement. With the departures of Jenner and Milano, T. Rowe boasts fewer exceptional funds, but most are still pretty good.
Steven T. Goldberg is an investment adviser in the Washington, D.C. area.
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

-
Are COVID Shots Still Covered By Medicare?
Getting the new COVID-19 vaccine covered by Medicare isn't as easy this year as it was in the past. Here's what you need to know before you take a trip to your pharmacy.
-
How Digital Platforms Are Changing the Way You Invest in Gold
Investing in gold is easier than ever thanks to digital platforms. Learn how online tools are lowering costs, increasing transparency and making gold accessible to all investors.
-
Stocks Rise to Start Fed Week: Stock Market Today
The Nasdaq Composite and S&P 500 hit new record closing highs as Wall Street awaits the Fed's next rate cut.
-
S&P 500 Slips Ahead of Fed Week: Stock Market Today
All eyes are on the Federal Reserve ahead of next week's critical policy meeting.
-
Dow Gains 617 Points as Rate Cuts Near: Stock Market Today
Wednesday's economic data didn't shift Wall Street's expectations that the Fed is preparing for a rate cut at next week's meeting.
-
S&P 500 Hits New High After Oracle Earnings: Stock Market Today
Another down day for Apple held the Dow Jones Industrial Average back, though.
-
Stocks Grind Up to New All-Time Highs: Stock Market Today
UnitedHealth stock led the Dow Jones Industrial Average amid increasing signs the labor market has not been well for months.
-
Markets Prepare for August Inflation Data: Stock Market Today
Apple CEO Tim Cook is still important, but price action this week is as much about incoming inflation data ahead of next week's Fed meeting.
-
Stocks Slip as Job Growth Stalls: Stock Market Today
The August jobs report came in much weaker than expected, while the unemployment rate ticked higher.
-
S&P 500 Hits New High on Jobs Friday Eve: Stock Market Today
The S&P 500 hit a new all-time closing high and most of the stocks in the Dow Jones Industrial Average were up the day before a critical jobs report.